Middle East & Africa Injection Pen Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Disposable Injection Pens and Reusable Injection Pens), Therapy (Diabetes, Growth Hormone Therapy, Autoimmune Diseases, Fertility, Cancer, and Ot

Middle East & Africa Injection Pen Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Disposable Injection Pens and Reusable Injection Pens), Therapy (Diabetes, Growth Hormone Therapy, Autoimmune Diseases, Fertility, Cancer, and Others Therapy), and End User (Hospitals and Clinics, Home Care, and Others)

The Middle East & Africa injection pen market is expected to grow from US$ 2,016.10 million in 2022 to US$ 2,872.94 million by 2028. It is estimated to register a CAGR of 6.1% from 2022 to 2028.

Increase in Biologics Patent Expiry and Use of Biosimilars in Middle East & Africa Injection Pen Market

Biologics are widely developed for treating chronic disorders such as cancer, multiple sclerosis, and diabetes. These drugs are unique in their own way, and manufacturers own patents of 20 years for manufacturing and distributing such drugs. As most patents are either expired or on the verge of expiry, other market players have begun launching their own version of such drugs, i.e., biosimilars. Biosimilars (generic drugs that are low-priced and are preferred by the government and insurance companies) have gained tremendous traction in the past few years over the original biologics. The pharmaceutical market players are promoting the adoption of biosimilars, which further creates the demand for injection pens for their delivery. As per AJMC, a total of 40 biosimilars were approved, and 25 new biosimilars were launched in the US till December 2022. Furthermore, there has been significant use of injectables on a large scale owing to prompt response, thus, generating the demand for injection pens for safe. Furthermore, the manufacturers of injection pens are constantly providing training for the proper use of injection pens to avoid associated dangers such as needle stick injuries and hyperglycemia which are further expected to create opportunities for the injection pen market. Therefore, increased use of biosimilars, patent expiry, and increased use of injectables are likely to create ample opportunity for the growth of the injection pen market in the coming years.

Middle East & Africa Injection Pen Market Overview

The Middle East & Africa injection pen market is segmented into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa. The market growth in this region is attributed to the increasing incidence of diabetes and infertility and growing efforts by companies for product development. The incidence of diabetes in Saudi Arabia is increasing rapidly and is expected to remain consistently high in the coming years due to the presence of a high percentage of obese and overweight citizens. According to the World Health Organization (WHO), children from Saudi Arabia are more likely to develop diabetes at an early age due to an unhealthy lifestyle and insufficient physical activity, and the prevalence of juvenile diabetes has been observed to be increasing continuously in the country in recent years. According to a report by the IDF, 10% of people from Saudi Arabia have diabetes, and the prevalence will almost double by 2045. Moreover, ~4.27 million Saudi Arabians have diabetes, and 1.86 million are yet to be diagnosed with the disease. This number is expected to reach 5.6 million and 7.5 million by 2030 and 2045, respectively.

Middle East & Africa Injection Pen Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Injection Pen Market Segmentation

The Middle East & Africa injection pen market is segmented on the basis of type, therapy, end user, and country. Based on type, the injection pen market is segmented into disposable injection pens and reusable injection pens. The disposable injection pens segment registered a larger market share in 2022.

Based on therapy, the Middle East & Africa injection pen market is segmented into diabetes therapy, growth hormone therapy, autoimmune diseases therapy, fertility therapy, cancer therapy, and others . The diabetes therapy segment registered the largest market share in 2022.

Based on end user, the Middle East & Africa injection pen market is segmented into hospitals & clinics , home care, and others. The home care segment registered the largest market share in 2022.

Based on country, the Middle East & Africa injection pen market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. The Rest of Middle East & Africa dominated the market in 2022.

AstraZeneca Plc, Becton Dickinson and Co, Eli Lilly, and Co, Gerresheimer AG, Haselmeier GmbH, Merck KGaA, Novo Nordisk AS, Owen Mumford Ltd, Sanofi SA, and Teva Pharmaceutical Industries Ltd are among the leading companies operating in the Middle East & Africa injection pen market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa injection pen market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa injection pen market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the injection pen market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution